Aurinia Pharmaceuticals Reports Strong Revenue Growth and Expands Share Repurchase Plan

Aurinia Pharmaceuticals ( (AUPH) ) has provided an announcement.

Aurinia Pharmaceuticals reported a significant increase in revenue for the first half of 2025, driven by strong sales of its flagship product, LUPKYNIS. The company also announced an increase in its share repurchase plan and raised its full-year revenue guidance, reflecting confidence in its market position and future growth prospects. Additionally, Aurinia is advancing its pipeline with positive results from a Phase 1 study of aritinercept, indicating potential expansion into treatments for other autoimmune diseases.

The most recent analyst rating on (AUPH) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Spark’s Take on AUPH Stock

According to Spark, TipRanks’ AI Analyst, AUPH is a Outperform.

Aurinia Pharmaceuticals has a solid overall stock score, driven by strong financial performance and positive earnings call highlights. However, the high valuation and mixed technical signals, along with potential risks from patent litigation and market competition, moderate the score.

To see Spark’s full report on AUPH stock, click here.

More about Aurinia Pharmaceuticals

Aurinia Pharmaceuticals is a biopharmaceutical company focused on delivering therapies for people living with autoimmune diseases. Its primary product is LUPKYNIS, the first FDA-approved oral therapy for treating adult patients with active lupus nephritis.

Average Trading Volume: 1,539,616

Technical Sentiment Signal: Buy

Current Market Cap: $1.21B

For a thorough assessment of AUPH stock, go to TipRanks’ Stock Analysis page.